FLINT, Mich. — Aug. 3, 2017 — The nation’s largest independent specialty pharmacy will dispense NITYR™ (nitisinone) tablets for hereditary tyrosinemia type 1.

Diplomat Pharmacy, Inc. (NYSE: DPLO), has been selected by Cycle Pharmaceuticals as the exclusive pharmacy to dispense NITYR™ (nitisinone) twice-daily tablets, recently approved by the Food and Drug Administration.

NITYR is indicated to treat hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.

To learn more about Diplomat’s rare disease program, visit diplomat.is/areas-of-excellence/rare-diseases.

NITYR, a formulation of nitisinone, is an alternative to capsules and oral suspension. The small tablets do not require refrigeration, and infants or patients with problems swallowing can take NITYR through an oral syringe.

“At Diplomat, our care team works vigorously to ensure our patients receive innovative therapy solutions while providing the high-touch care they deserve,” said Paul Urick, Diplomat’s president. “As the sole distributor, we are excited to offer a new treatment option for patients seeking a more convenient therapy and in need of support. Cycle Pharmaceuticals has interpreted the modern health needs of HT-1 patients and caregivers by successfully developing a new treatment to improve their quality of life.”

HT-1 is a rare genetic disease that is usually diagnosed at birth. Children with this disorder lack an enzyme needed to break down tyrosine. The deficiency causes tyrosine and its metabolites to build up in the liver, kidneys, and central nervous system and can cause liver failure, kidney dysfunction, and neurological problems.

Symptoms vary on a case-by-case basis and can include failure to gain weight; diarrhea; vomiting; enlarged, tumorous, or failing liver; fluid accumulation in the peritoneal cavity; kidney failure; neurological problems; and bone softening.

HT-1 affects males and females in equal numbers. The prevalence has been estimated to be 1 in 100,000 to 120,000 births worldwide.

NITYR is a registered trademark of Cycle Pharmaceuticals Limited in the United Kingdom. For more information about NITYR, visit nityr.us.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended Dec. 31, 2016, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.

About Diplomat

Diplomat (NYSE: DPLO) is the nation’s largest independent provider of specialty pharmacy services—helping patients and providers in all 50 states. The company offers medication management programs for people with complex chronic diseases and delivers unique solutions for manufacturers, hospitals, payors, providers, and more. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information, visit diplomat.is. 


Kali Lucas, Public Relations Specialist
810.768.9580 | press@diplomat.is

Gary Rice, RPh, MS, MBA, CSP
Executive Vice President of Operations
810.768.9863 | grice@diplomat.is